About Dermavant
Dermavant is a company based in Phoenix (United States) founded in 2016 was acquired by Organon in September 2024. Dermavant has raised $160 million across 2 funding rounds from investors including Marathon Asset Management, NovaQuest Capital Management and Organon. Dermavant offers products and services including VTAMA Cream. Dermavant operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Sol-Gel Technologies, Bausch Health and Hugel, among others.
- Headquarter Phoenix, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dermavant Sciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$160 M (USD)
in 2 rounds
-
Latest Funding Round
$160 M (USD), Series D
Jun 08, 2021
-
Investors
Marathon Asset Management
& 2 more
-
Employee Count
Not available
-
Acquired by
Organon
(Sep 18, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dermavant
Dermavant offers a comprehensive portfolio of products and services, including VTAMA Cream.
Cream for treating chronic skin conditions like psoriasis.
People of Dermavant
Unlock access to complete
Unlock access to complete
Leadership Team
88 people
Software Development Team
55 people
Finance and Accounting
29 people
Data Analysis and Operations Team
22 people
Legal and Compliance
19 people
Operations Team
17 people
Product Management Team
15 people
Human Resources and Administration
14 people
Unlock access to complete
Funding Insights of Dermavant
Dermavant has successfully raised a total of $160M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $160 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dermavant
Dermavant has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Marathon Asset Management, NovaQuest Capital Management and Organon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm focused on life science and healthcare companies
|
Locked | Locked | Locked | |
|
Diversified investment management services are provided across asset classes.
|
Locked | Locked | Locked | |
|
Organon is focused on improving women's health globally.
|
Locked | Locked | Locked |
Investor details for Dermavant
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dermavant
Investment portfolio details for Dermavant
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dermavant
Detailed financials for Dermavant
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dermavant Comparisons
Peer comparison for Dermavant
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dermavant
Dermavant operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Sol-Gel Technologies, Bausch Health and Hugel, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
Detailed competitors of Dermavant
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dermavant
Complete news archive for Dermavant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dermavant
Dermavant was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Dermavant is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
Todd Zavodnick is the current CEO of Dermavant.
Dermavant is a funded company, having raised a total of $160M across 2 funding rounds to date.
Dermavant was founded in 2016 and is headquartered in Phoenix, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are developed for inflammatory skin conditions. The lead candidate, DMVT-505, targets psoriasis and atopic dermatitis by modulating AhR and inhibiting proinflammatory factors. Additional products include DMVT-502, in Phase 1 trials for atopic dermatitis and vitiligo, and DMVT-504 for primary focal hyperhidrosis.
Dermavant's top competitors include Revance Therapeutics, Bausch Health and Sol-Gel Technologies.
Dermavant offers VTAMA Cream.
Dermavant has 3 investors. Key investors include Marathon Asset Management, NovaQuest Capital Management, and Organon.